Category Archives: CAPRISA

  1. Microbicide hits snag: It’s about the money honey

    via New York Times, by Celia Dugger When scientists celebrated the announcement in July that a vaginal microbicide had finally been found that significantly reduced H.I.V. infections in women, there was still a prosaic — though essential — piece of the puzzle missing: money. Donors have not committed enough money for even one of the two studies Read More >>

    CAPRISA, HIV/AIDS policy, new prevention technologies, research, South Africa, vaginal microbicide
  2. Communities debate microbicide results in South Africa

    via PlusNews The recent release of positive results from a microbicide trial in South Africa have kick-started discussions between scientists, activists and community workers about the quickest and most responsible way of getting a product into women’s hands. The trial by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) found that a vaginal Read More >>

    advocacy, CAPRISA, South Africa, Tenofovir, vaginal microbicide
  3. New York Times Examines Questions Left Unanswered By Microbicide Trial

    Via Kaiser Daily Global Health Policy Report The New York Times examines a set of questions raised by news out of the International AIDS Conference-AIDS 2010 last week that a microbicide gel containing the antiretroviral (ARV) tenofovir used by women before and after sex helped reduce their risk of HIV infection by 39 percent. “After more than Read More >>

    AIDS 2010, CAPRISA, IAC, Microbicides, Vienna
  4. The CAPRISA 004 by Ida Jooste (“Gabi’s Gift”)

    The top news story of the Vienna 2010 AIDS conference was the encouraging results from the CAPRISA 004 study, showing that a tenofovir microbicide gel provided 39% protection against HIV. In 2007 Gabi Nxele volunteered to be a participant in the study to test the efficacy of the gel for the prevention of HIV infection in women. Read More >>

    AIDS 2010, CAPRISA, Microbicides
  5. CAPRISA microbicide results explained on You Tube

    CAPRISA, clinical trials, HIV transmission, HSV-2, new prevention technologies, research, South Africa, vaginal microbicide
  6. Positive Results from a Microbicide Trial – an overview of media coverage

    The HIV prevention world is abuzz with excitement following news of the first clinical evidence that a vaginal gel – known as a microbicide – can help to prevent sexual transmission of HIV infection. A study by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) found that a vaginal gel containing the antiretroviral Read More >>

    CAPRISA, HIV transmission, HSV-2, International AIDS Conference, new prevention technologies, research, South Africa, Tenofovir, vaginal microbicide, Vienna
  7. HIV Prevention Science Scores a Victory – The Gel Works!

    IRMA media releaseIRMA Presses for Intensified Rectal Microbicide Research Quarraisha Abdool Karim (left) and Salim Abdool Karim,  co-principal investigators of the CAPRISA 004 trial. Vienna, Austria July 19, 2010 – Today at the XVIII International AIDS Conference in Vienna, Austria, members of the International Rectal Microbicide Advocates (IRMA) and thousands of other HIV advocates and scientists cheered Read More >>

    CAPRISA, clinical trials, HIV transmission, HSV-2, IRMA, new prevention technologies, research, South Africa, Tenofovir, vaginal microbicide
  8. DSMB recommends tenofovir gel trial continue

    A Data and Safety Monitoring Board (DSMB) held a scheduled review of the CAPRISA 004 Tenofovir Gel Phase IIb trial on 27 July 2009. This microbicide trial is assessing the safety and effectiveness of 1% tenofovir gel to prevent HIV infection in women in South Africa. It is a collaborative effort between the Centre for the AIDS Read More >>

    CAPRISA, DSMB, research, South Africa, Tenofovir, vaginal microbicide